Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 85 – KANALRAD
2023-505972-32-00Phase 3Authorised
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jan 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, cisplatin, fluorouracil, mitomycin c and capecitabine in anal squamous cell carcinoma (SCCA) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Disease-related event-free survival. Planned start Jan 2024; status: authorised.
02
Drugs
docetaxelcisplatinfluorouracilmitomycin ccapecitabine
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2023-505972-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505972-32-00.